In pharma, we all know that things usually move slowly…
Except right now, there’s real movement around recombinant bacterial endotoxin tests (BET) like rFC and rCR (previously called rLAL).
But how are these methods viewed by different pharmacopoeias?
Are they considered compendial methods or alternative methods?
To find out, we took a look at several pharmacopoeias, here’s what we found.
Compendial or Alternative Methods: What Do the Pharmacopoeias Say?
Here’s a summary table for the different pharmacopoeias:
| rFC recombinant Factor C | rCR recombinant full cascade | |
| USP <86> in-process, raw material,product with updated monograph | Compendial* | Compendial* |
| USP <86> Product without updated monograph | compendial alternative method | compendial alternative method |
| EU 2.6.32 in-process, raw material,product with updated monograph | Compendial | Alternative |
| EU 2.6.32 Product without updated monograph | Alternative | Alternative |
| Indian 2.2.3 | Alternative | Alternative |
| Chinese ChP 9251 | Alternative | Alternative |
| Korean Test No. 23 | Alternative | Alternative |
| Brazilian 5.5.2.7.3 | Alternative | Alternative |
| Japanese G4-4-180 | Alternative | Alternative |
* May require additional data for primary validation.
It’s clear that the U.S. Pharmacopoeia (USP) is currently the most advanced in recognizing recombinant methods.
However, one important point to note: as of the time of writing this article (June 2025), no monograph yet refers to chapter <86>.
So for now, recombinant methods are still considered alternative and must be validated as such.
Lack of Harmonization Between Pharmacopoeias
Likewise, even if you’re based in a country where the pharmacopoeia considers your method compendial, don’t forget to check the regulations in the countries where your products will be marketed.
If one of those countries doesn’t recognize the method as compendial, you’ll need to validate it as an alternative method.
This is the core issue with the lack of harmonization (for now) between pharmacopoeias regarding recombinant methods… but it’s probably only a matter of time!
Validation of Recombinant Methods: What Do the Pharmacopoeias Expect?
Now that we know whether a method is considered compendial or alternative, let’s look at how this affects the validation process.
Indeed, the biggest difference between a compendial method and an alternative method lies in how they must be validated.
Here’s a summary table of what pharmacopoeias may require during validation:
| Compendial | Alternative | Compendial alternative method |
| Method suitability | Comparison study with LAL | Primary Validation |
| Method suitability | Comparison study with LAL | |
| Method suitability |
Validating an Alternative Method: A Simple and Quick Process
If the method you’ve chosen is considered alternative, don’t worry.
Based on discussions with several labs, validating a bacterial endotoxin test is nothing like validating a rapid microbiological method (RMM), which can take months or even years.
In this case, validating a product usually takes 2 to 3 days, with no more than 4 hours of work per day.
“Validating an alternative method for endotoxin testing isn’t that complicated.”
A SuperMicrobiologist
Practical Tip: Include Naturally Contaminated Samples in Your Validation
During validation, it’s common to work with endotoxin-spiked samples. But as with any artificial contamination, it doesn’t always reflect real-world conditions.
That’s why we recommend adding a few naturally contaminated product samples to your validation protocol.
Even though it’s not required by the pharmacopoeia, it will give you greater confidence in your detection method.
See, for example, the scientific publication by Kikuchi:
The results clearly showed significant differences between naturally contaminated samples and those artificially spiked.
Conclusion: Recombinant BET Are Growing – Be Ready
Even though recombinant methods are not yet fully harmonized worldwide, they are increasingly recognized and represent a truly sustainable alternative to LAL.
More ethical, more stable, rFC and rCR tests are expected to become the new standard in the future.
In the meantime, it’s essential to clearly understand their regulatory status, adapt your validation strategy accordingly… and keep an eye on pharmacopoeial updates!